Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital Tufting Enteropathy is a rare congenital enteropathy presenting with early-onset severe and intractable diarrhea that leads to irreversible intestinal failure.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Growth and development | 1 | Failure to thrive |
Digestive system | 1 | Intractable diarrhea |
Muscles | 1 | Villous atrophy |
Bones and joints | 1 | Joint inflammation (arthritis) |
Individuals with Lynch syndrome are at increased risk for colorectal cancer (CRC) and other cancers including those of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Table 3. Cancer Risks by Gene in Individuals with Lynch Syndrome by Age 70 Years Compared to the General Population
CancerLocation | GeneralPopulationRisk by Age 741 | Cancer Risk by Age 702,3 |
|---|---|---|
EPCAM F | M | F |
Any | 20% | 78% |
Colorectum | 2%4 | 44% |
Endometrium | 1%4 | 35% |
13% | 12%5 Ovary | 0.7% |
3% | Stomach | 1% |
Small bowel | 1% Ureter, kidney | 1% |
Urinary bladder | 1% | 3% |
Prostate | 4% | 7% |
16% | 5% | 5% |
Brain | 1% | 2% |
Breast | 5%4 | 11% |
Source: GeneReviews — "Lynch Syndrome"
EPCAM encodes epithelial cell adhesion molecule (314 aa). May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Highest expression in Colon Transverse (347.0 TPM) and Small Intestine Terminal Ileum (309.3 TPM).
Congenital diarrhea 5 with tufting enteropathy is associated with mutations in the EPCAM gene on chromosome 2.
The EPCAM protein participates in Hormone receptor positive mammary luminal progenitor cell produces hormone receptor positive luminal epithelial cell, Mammary stem cell produces myoepithelial/basal progenitor, and Embryonic ectoderm cell produces mammary stem cell pathways.
EPCAM is classified as a druggable target (Cell Surface, Clinically Actionable, and Druggable Genome categories) with score 6.3.
EPCAM. The risk for extracolonic cancers is dependent on the size of the deletion. 3' EPCAM deletions have been shown to confer a lower risk for extracolonic cancers, whereas deletions that extend into MSH2 confer extracolonic cancer risks similar to intragenic MSH2 pathogenic variants .
Source: GeneReviews — "Lynch Syndrome"
Penetrance of CRCs and extracolonic cancers associated with pathogenic variants in an MMR gene or EPCAM is less than 100% . Therefore, some individuals with a cancer-predisposing pathogenic variant in an MMR gene or EPCAM may never develop cancer.
Source: GeneReviews — "Lynch Syndrome"
No consensus clinical diagnostic criteria for Lynch syndrome have been published.
A diagnosis of Lynch syndrome should be suspected in a proband with:
A diagnosis of a tumor of the Lynch syndrome spectrum (e.g., colorectal, endometrial, ovarian, stomach, small bowel, urinary tract [urothelial], biliary tract, prostate, brain [usually glioblastoma], skin [sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas], and pancreas) with one of the following on tumor tissue
testing:
Source: GeneReviews — "Lynch Syndrome"
Hereditary Cancer Syndromes Table 4. Hereditary Cancer Syndromes with Increased Risk of Colorectal Cancer in the Differential Diagnosis of Lynch Syndrome
Gene(s) | Disorder | MOI | Polyps | Colorectal Cancer | Other Associated Cancers / Clinical Manifestations |
|---|---|---|---|---|---|
RPS20 | RPS20-assoc hereditary nonpolyposis CRC1 | AD | No |
Genetic testing for EPCAM is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for congenital diarrhea 5 with tufting enteropathy has been reported in the published literature.
No approved treatments are currently available for congenital diarrhea 5 with tufting enteropathy. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with Lynch syndrome, the evaluations summarized in are recommended.
Table 6.
Recommended Evaluations Following Initial Diagnosis in Individuals with Lynch Syndrome
System/Concern | Evaluation | Comment
| Colonoscopy w/removal of precancerous polyps1 | Beginning between ages 20 25 yrs or 2-5 yrs before earliest CRC diagnosis in family, whichever is earlier
| Educate females re symptoms of endometrial cancers (e.g., abnormal uterine bleeding, postmenopausal bleeding). | Eval of symptoms should incl endometrial biopsy every 1-2 yrs2
Screening by endometrial biopsy2 | Beginning between ages 30 35 yrs
| Educate females re symptoms assoc w/ovarian cancer (e.g., pelvic or abdominal pain, bloating, abdominal girth, difficulty eating, early satiety, urinary frequency or urgency). | Symptoms that persist for several wks are a change from baseline should prompt eval by physician.
Gastric duodenal
cancers | • Consider upper endoscopy exam esp for those w/family history of gastric cancer those of Asian ancestry.
Biopsies should be evaluated for H pylori infections so that appropriate treatment can be given as needed.3
| Beginning at age 40 yrs
| Consider capsule endoscopy small bowel enterography. | In symptomatic persons
Urinary tract cancers
(renal pelvis, ureter,
Source: GeneReviews — "Lynch Syndrome"
There is accumulating evidence that a high body mass, cigarette smoking, type 2 diabetes, and high cholesterol increase the risk of CRC in Lynch syndrome. The direction and strength of observed associations are similar to those for the general population .
Source: GeneReviews — "Lynch Syndrome"
Chromoendoscopy vs narrow band imaging (NBI) vs high-definition white-light colonoscopy for Lynch syndrome surveillance. Two studies compared different colonoscopy imaging modalities against chromoendoscopy. In a study of 138 individuals with Lynch syndrome undergoing back-to-back colonoscopies (first with NBI followed by indigo carmine chromoendoscopy), the adenoma detection rate (ADR) for NBI alone was 20.3% while the ADR for both was 30.4%. A 10.1% difference in detection failed to reach the prespecified noninferiority assumption margin of 5% . In another study of 256 individuals with Lynch syndrome randomized to indigo carmine chromoendoscopy versus high-definition white-light colonoscopy, no significant difference in ADR was detected by pancolonic chromoendoscpy (34.4%; 95% CI 26.
Source: GeneReviews — "Lynch Syndrome"
View trials for congenital diarrhea 5 with tufting enteropathy
Table 8. Recommended Surveillance for Individuals with Lynch Syndrome
System/Concern | Evaluation | Frequency |
|---|---|---|
Colorectal cancer | Colonoscopy w/removal of precancerous polyps1 | Every 1-2 yrs beginning between ages 20 25 yrs or 2-5 yrs before earliest CRC diagnosis in the family, whichever is earlier Endometrial |
cancer | Educate females re symptoms of endometrial cancers (e.g., abnormal uterine bleeding, postmenopausal bleeding). | Annually Consider transvaginal ultrasound exam endometrial biopsy2 |
Ovarian cancer | Educate females re symptoms assoc w/ovarian cancer (e.g., pelvic or abdominal pain, bloating, abdominal girth, difficulty eating, early satiety, urinary frequency or urgency). | Annually Gastric duodenal cancers |
Distal small bowel | Consider capsule endoscopy small bowel enterography. | In symptomatic persons Urinary tract cancers (renal pelvis, |
ureter, /or bladder) | Consider urine analysis w/urine cytology to identify microscopic hematuria in those w/family history of urothelial cancer.4 | Annually beginning between ages 30 35 yrs |
Pancreatic cancer | Consider pancreatic cancer screening in those w/family history of pancreatic cancer w/alternating EUS /or MRI/MRCP | Annually Other cancers; Follow general population screening guidelines seek prompt medical attention for changes in health or persistent symptoms. |
Source: GeneReviews — "Lynch Syndrome"
Phenotype severity distribution: 3 always present features, 1 common feature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for congenital diarrhea 5 with tufting enteropathy.
106 publications have been identified in PubMed for congenital diarrhea 5 with tufting enteropathy. Research spans Basic Science / Preclinical (51%), Review / Meta-Analysis (33%), and Diagnostic / Biomarker (4%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 54 | 51% |
Research summaries | 35 | 33% |
Testing and diagnosis research | 4 | 4% |
Clinical study results | 4 | 4% |
Disease patterns and progression | 3 | 3% |
New treatment approaches | 3 | 3% |
Patient case studies | 2 | 2% |
Singh J (2026). [PMID: 41490203](https://pubmed.ncbi.nlm.nih.gov/41490203/). *Cardiovasc Res*. [Review / Meta-Analysis]
Noyan A (2026). [PMID: 42172468](https://pubmed.ncbi.nlm.nih.gov/42172468/). *Turk J Pediatr*. [Review / Meta-Analysis]
Liang L (2026). [PMID: 41380997](https://pubmed.ncbi.nlm.nih.gov/41380997/). *Mol Cell Proteomics*. [Basic Science / Preclinical]
Shukla UV (2026). [PMID: 33620856](https://pubmed.ncbi.nlm.nih.gov/33620856/). *Unknown Journal*. [Basic Science / Preclinical]
Luna G (2026). [PMID: 41558485](https://pubmed.ncbi.nlm.nih.gov/41558485/). *Dev Cell*. [Basic Science / Preclinical]
Zhao X (2025). [PMID: 40075093](https://pubmed.ncbi.nlm.nih.gov/40075093/). *Int J Oral Sci*. [Basic Science / Preclinical]
Adeva-Andany MM (2025). [PMID: 40326264](https://pubmed.ncbi.nlm.nih.gov/40326264/). *Curr Rev Clin Exp Pharmacol*. [Review / Meta-Analysis]
Camisa C (2025). [PMID: 41056121](https://pubmed.ncbi.nlm.nih.gov/41056121/). *Cutis*. [Review / Meta-Analysis]
Yoshihara M (2025). [PMID: 40473205](https://pubmed.ncbi.nlm.nih.gov/40473205/). *Ocul Surf*. [Case Report / Case Series]
Reichert D (2025). [PMID: 39930235](https://pubmed.ncbi.nlm.nih.gov/39930235/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 6:01 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about congenital diarrhea 5 with tufting enteropathy
High (MMR proficient tumors)
Adult |
APC | Familial adenomatous polyposis (FAP) (See APC-Assoc Polyposis Conditions.) | AD | Colonic, gastric duodenal adenomas (100 cumulative polyps) | ~100% if untreated | 39 (range: 34-43); Polyp diagnosis: 16 (range: 7-36) |
risk of medulloblastoma, thyroid papillary carcinoma, hepatoblastoma, pancreatic, gastric duodenal cancers Attenuated familial adenomatous polyposis (AFAP) (See APC-Assoc Polyposis Conditions.) | AD | Colonic, gastric duodenal adenomas (10-100 cumulative polyps) | 70% by age 80 yrs | 50 | Upper GI findings thyroid duodenal cancer risks are similar to FAP.; Other extraintestinal manifestations are unusual.; Desmoid tumors assoc w/3' APC variants |
POLE | Polymerase proofreading-assoc polyposis (PPAP) (See OMIM 615083.) | AD | Colonic adenomas (0-100 cumulative polyps) | 30%-40% by age 70 yrs2; CRC may develop in absence of polyposis. | — |
Note: Most CRCs are MSS; some are MSI high. | 502 | risk of cancers of endometrium, ovary, brain, breast, other tumor types; Adenomas in upper GI tract | — | — | — |
POLD1 | Polymerase proofreading-assoc polyposis (PPAP) (See OMIM 612591.) | AD | Colonic adenomas (0-100 cumulative polyps) | 50%-60% by age 70 yrs2; CRC may develop in absence of polyposis. | — |
Note: Most CRCs are MSS; some are MSI high. | 35-402 | risk of cancers of endometrium, ovary, brain, breast, other tumor types; Adenomas in upper GI tract MUTYH | — | — | — |
MUTYH polyposis | AR | Colonic adenomas (10-100 cumulative polyps); Hyperplastic /or serrated polyps may occur.; Duodenal adenomas | 43%-63% by age 60 yrs; 80%-90% lifetime risk if untreated; CRC may develop in absence of polyposis | — | — |
Note: Most CRCs are MSS; a minority are MSI high. | 48 | Duodenal adenomas are common w/ risk of duodenal cancer.; risk of ovarian bladder malignancies; Additional features: thyroid nodules, benign adrenal lesions, jawbone cysts, CHRPE NTHL1 | — | — | — |
NTHL1 tumor syndrome | AR | Colonic adenomas (1-100 cumulative polyps); Hyperplastic /or serrated polyps may occur. | — | — | — |
Duodenal adenomas | High lifetime risk | 613 | High risk of multiple primary tumors; risk of breast endometrial cancers other tumors types: cervical, urothelial carcinoma of the bladder, meningiomas, unspecified brain tumors, basal cell carcinomas, head neck squamous cell carcinomas, hem... | — | — |
Source: GeneReviews — "Lynch Syndrome"